SCHEMBL19902582

SCHEMBL19902582

O=C(N[C@H]1CC[C@H](c2n[nH]c(=O)c3ccccc32)CC1)c1cccc(-n2ccnc2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 1/20 0.47
PDE4A P27815 1/20 0.43
PDE4B Q07343 1/20 0.43
PDE4C Q08493 1/20 0.43
PDE4D Q08499 1/20 0.43
CD38 P28907 6/20 0.43
ROCK2 O75116 2/20 0.42
ABL1 P00519 1/20 0.41
PRMT5 O14744 1/20 0.41
WDR77 Q9BQA1 1/20 0.41
CTSV O60911 2/20 0.40
CTSL P07711 2/20 0.40
CTSB P07858 2/20 0.40
CTSS P25774 2/20 0.40
CTSK P43235 2/20 0.40
MAP3K5 Q99683 1/20 0.39
CYP4Z1 Q86W10 1/20 0.38
ALDH1A1 P00352 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
NPC1 O15118 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19902714 0.90 ROCK1 (0.58) ROCK1PDE4APDE4BPDE4CPDE4D
SCHEMBL17452887 0.89 ROCK2 (0.56) ROCK1PDE4APDE4BPDE4CPDE4D
SCHEMBL19902586 0.85 ROCK2 (0.45) ROCK1ROCK2MAP3K5ALDH1A1L3MBTL1
SCHEMBL17452877 0.79 ROCK2 (0.56) ROCK1PDE4APDE4BPDE4CPDE4D
SCHEMBL25135545 0.79 NPC1 (0.55) CD38ABL1CTSVCTSLCTSB
SCHEMBL30363943 0.79 NPC1 (0.55) CD38ABL1CTSVCTSLCTSB
SCHEMBL25135518 0.78 KHK (0.50) PDE4APDE4BPDE4CPDE4DCD38
SCHEMBL25135607 0.78 RAB9A (0.57) CD38ABL1CTSVCTSLCTSB
Hydrochloric Acid SCHEMBL30363722 0.77 KHK (0.49) PDE4APDE4BPDE4CPDE4DCD38
SCHEMBL19902632 0.76 KMT2A (0.51) ROCK1ROCK2PRMT5L3MBTL1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK BRISTOL MYERS SQUIBB CO (US) 2018-06-07 US disclosed
US-9902702-B2 Spirocycloheptanes as inhibitors of rock BRISTOL-MYERS SQUIBB COMPANY (US) 2018-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK ROCK1, MYLK, ROCK2 ROCK1 1/4885PDE4A 222/4885PDE4B 342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.